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OBJECTIVE — Assignment of the correct molecular diagnosis in diabetes is necessary for
informed decisions regarding treatment and prognosis. Better clinical markers would facilitate
discrimination and prioritization for genetic testing between diabetes subtypes. Serum 1,5 an-
hydroglucitol (1,5AG) levels were reported to differentiate maturity-onset diabetes of the young
due to HNF1A mutations (HNF1A-MODY) from type 2 diabetes, but this requires further
validation. We evaluated serum 1,5AG in a range of diabetes subtypes as an adjunct for deﬁning
diabetes etiology.
RESEARCH DESIGN AND METHODS — 1,5AG was measured in U.K. subjects with:
HNF1A-MODY (n  23), MODY due to glucokinase mutations (GCK-MODY, n  23), type 1
diabetes (n  29), latent autoimmune diabetes in adults (LADA, n  42), and type 2 diabetes
(n  206). Receiver operating characteristic curve analysis was performed to assess discrimina-
tive accuracy of 1,5AG for diabetes etiology.
RESULTS — Mean (SD range) 1,5AG levels were: GCK-MODY 13.06 g/ml (5.74–29.74),
HNF1A-MODY 4.23 g/ml (2.12–8.44), type 1 diabetes 3.09 g/ml (1.45–6.57), LADA 3.46
g/ml (1.42–8.45), and type 2 diabetes 5.43 (2.12–13.23). Levels in GCK-MODY were higher
than in other groups (P  10
4 vs. each group). HNF1A-MODY subjects showed no difference
in unadjusted 1,5AG levels from type 2 diabetes, type 1 diabetes, and LADA. Adjusting for A1C
revealed a difference between HNF1A-MODY and type 2 diabetes (P  0.001). The discrimi-
native accuracy of unadjusted 1,5AG levels was 0.79 for GCK-MODY versus type 2 diabetes and
0.86 for GCK-MODY versus HNF1A-MODY but was only 0.60 for HNF1A-MODY versus type
2 diabetes.
CONCLUSIONS — In our dataset, serum 1,5AG performed well in discriminating GCK-
MODYfromotherdiabetessubtypes,particularlyHNF1A-MODY.Measurementof1,5AGlevels
could inform decisions regarding MODY diagnostic testing.
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A
n estimated 2% of diabetes in Eu-
rope is caused by monogenic disor-
ders of the -cell (maturity-onset
diabetes of the young [MODY]) (1). The
two most common types of MODY in
clinical practice are caused by mutations
in the genes encoding hepatocyte nuclear
factor 1- (HNF1A) and glucokinase
(GCK) (1). Making the correct molecular
diagnosis allows individualization of
treatment, for example the use of low-
dose sulfonylurea as a ﬁrst line in MODY
due to HNF1A mutations (HNF1A-
MODY) (2). It also conveys important in-
formation about prognosis and guides
investigation of family members. Despite
these clear advantages, individuals with
MODY are frequently misdiagnosed as
having either type 1 or type 2 diabetes or
do not have conﬁrmatory molecular test-
ing performed even when MODY is
suspected.
AlthoughHNF1A-MODYandMODY
due to GCK mutations (GCK-MODY)
have distinct phenotypes (1,3), differen-
tiating these from each other and from
common forms of diabetes can be chal-
lenging in clinical practice. Molecular ge-
netictesting,ifpositive,isdeﬁnitivebutis
currentlytooexpensiveforindiscriminate
use. Therefore, there is a need for novel
biochemical screening tools to identify
and direct efﬁcient genetic analysis in
thoseforwhomaprobablemonogenicdi-
agnosis of diabetes exists. Ideally such a
test would be highly speciﬁc for a MODY
subtype and would allow differentiation
between type 1 and type 2 diabetes.
A recent report suggests that mea-
surement of serum 1,5 anhydroglucitol
(1,5AG)mayrepresentsuchatest,atleast
todiscriminateHNF1A-MODYfromtype
2 diabetes (4). 1,5AG is a metabolically
inactive monosaccharide that reaches
steady state between ingestion and uri-
nary excretion with near complete renal
reabsorption at a speciﬁc fructose-
mannose active transporter (5,6). Due to
structural similarity, glucose competi-
tivelyinhibitsthisreabsorption,suchthat
intimesofsigniﬁcantglycosuria,1,5AGis
excreted in the urine and consequently
serum levels fall (7). Thus, poor glycemic
control is associated with low serum
1,5AGlevels(8).Alowrenalthresholdfor
glucose also results in a serum 1,5AG
level lower than expected (9). As HNF1A
mutations are characterized by low renal
glucose threshold (10) due to decreased
expression of the high-afﬁnity low-
capacity glucose co-transporter 2
(SGLT2) (11), it was hypothesized that
1,5AG levels could be a biomarker for
HNF1A-MODY. An initial report of se-
rum 1,5AG levels in Polish subjects (4)
found that mean 1,5AG levels were 50%
lower in patients with HNF1A-MODY
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matched for glycemic control.
Wesoughttoevaluatethishypothesis
in a larger independent sample set with a
wider range of diabetes subtypes and to
assess the performance of serum 1,5AG
levels as an adjunctive test in identifying
subtypes of diabetes.
RESEARCH DESIGN AND
METHODS— Subjects were collected
inOxford,U.K.TheMODYsamplescom-
prise subjects with a conﬁrmed mutation
in either HNF1A (n  23 from 12 fami-
lies) or GCK (n  23 from 10 families).
Median family size was 2.5 members
(range 1–6), and half the families com-
prised only one individual. Nineteen of
theHNF1A-MODYsubjectshaddiabetes,
one had IGT, and three were normogly-
cemic. Oral glucose tolerance test
(OGTT) data from the time of sampling
were available for all nondiabetic
subjects.
Theremainingsubjectswerefromthe
Young Diabetes in Oxford (YDX) study,
comprising subjects diagnosed with dia-
betes 45 years of age recruited from ei-
ther primary (n  82) or secondary (n 
198) care. Within the group are cases of
classical type 1 diabetes (n  29), latent
autoimmune diabetes in adults (LADA,
n  42), and type 2 diabetes (n  209).
Type1diabeteswasdeﬁnedaspermanent
insulintreatmentsincediagnosiswithad-
ditional evidence of severe -cell dys-
function (C-peptide undetectable or
homeostasis model assessment of -cell
function [HOMA %B] 10%), positive
GAD antibodies (14 World Health Or-
ganization [WHO] units/ml), or both.
LADA was deﬁned as diabetes with posi-
tive GAD antibodies but no requirement
for insulin treatment within 3 months of
diagnosis. Those not requiring perma-
nent insulin treatment at diagnosis with
negativeantibodieswereclassiﬁedashav-
ing type 2 diabetes. Subjects in the type 2
diabetic group did not meet current clin-
ical criteria for MODY diagnostic testing
(12)orhadbeentestedandwerenegative
for mutations in HNF1A/HNF4A (n  9)
or GCK (n  4). Brieﬂy, clinical criteria
for HNF1A-MODY testing was young on-
set (25 years) of familial non–insulin
dependent diabetes and for GCK testing
wasyoungonsetofmildfastinghypergly-
cemia (5.5–8 mmol/l).
Two of the LADA subjects and 31 of
the type 2 subjects were of non-European
ethnicity (14 Asian, 11 Black, 1 Chinese,
and 7 mixed or other).
Clinical details, anthropometry, and
fasting blood samples were collected for
all subjects (Table 1). The study was ap-
provedbytheOxfordshireLocalResearch
Ethics Committee, and all subjects gave
informed consent.
1,5AG was measured using an enzy-
matic colorimetric assay (GlycoMark,
GlycoMark, NY) (13). Intra-assay coefﬁ-
cient of variance (CV) was 0.46%, and
inter-assay CV ranged from 1.74 to
2.37%. GADA was measured by a radio-
immunoassay using 35S-labeled full-
length GAD65, and results were expressed
in WHO units per milliliter derived from a
standard curve calibrated from interna-
tional reference material (National Institute
for Biological Standards and Control code
97/550). Samples were considered positive
if they had levels above 14 WHO units/ml
(97.5th percentile of healthy school chil-
dren) (14).
Values for age of diagnosis, duration
of diabetes, BMI, creatinine, A1C, fasting
plasma glucose (FPG) and 1,5AG level
were not normally distributed and were
log10 transformed. Geometric mean and
SD range were calculated. ANOVA was
calculated across the groups. For 1,5AG
levels, pairwise comparisons (using T test
with Bonferroni correction for multiple
testing) were also calculated between the
different diabetes subtypes. We then ex-
aminedtheeffectofcorrecting1,5AGlev-
els for A1C, and, in the type 2 diabetes
and MODY subgroups, for the effects of
treatment modality. As 1,5AG levels can
be lowered in chronic renal failure (15),
subjects with serum creatinine 150
mol/l were excluded from the analysis
(one subject with LADA and nine with
type 2 diabetes).
Receiver operating characteristic
(ROC) curve analysis was performed to
assess the discriminative accuracy of
1,5AG with regard to diabetes etiology.
The performance of 1,5AG level as a di-
agnostic discriminator was compared
with A1C and FPG. All statistical analysis
was performed in SPSS version 16, and
P  0.05 was assumed to be signiﬁcant.
RESULTS— Table 1 shows the char-
acteristics of the subjects and the results
of the biochemical investigations. Geo-
metric mean (SD range) 1,5AG levels
were: GCK-MODY 13.06 g/ml (5.74–
29.74), HNF1A-MODY 4.23 g/ml
(2.12–8.44), type 1 diabetes 3.09 g/ml
(1.45–6.57), LADA 3.46 g/ml (1.42–
8.45), and type 2 diabetes 5.43 g/ml
(2.12–13.23).
Upon ﬁrst examination of the unad-
justed data, we found no difference in
mean 1,5AG levels between subjects with
HNF1A-MODY and type 2 diabetes (P 
0.05). There was also no difference in
1,5AG levels between HNF1A-MODY
and either of the autoimmune groups
(P  0.05). As previously reported (16),
we found 1,5AG levels were higher in
thosewithtype2diabetescomparedwith
those in the autoimmune groups (type 2
vs. type 1 diabetes, P  0.011, type 2
diabetesvs.LADA,P0.015).Aftercon-
trollingforA1C,adjusted1,5AGlevelwas
lower in HNF1A-MODY than in type 2
diabetic subjects (P  0.001). Adjusting
for A1C did not alter the relationships be-
tween 1,5AG levels in the other diabetic
subgroups. Reanalysis adjusting for
shared family membership in the MODY
cases and excluding the non-European
individuals had no effect on these ﬁnd-
ings (data not shown). Duration of diabe-
tesalsodidnothaveasigniﬁcanteffecton
1,5AG levels, but in the type 2 diabetic
subjects we observed a progressively
lower 1,5AG level (and higher A1C) with
escalating treatment requirement. This
was not seen in the MODY subgroups.
The three panels in Fig. 1 show scatter
plots of unadjusted 1,5AG levels plotted
against A1C. These illustrate the consid-
erable overlap between HNF1A-MODY
and common forms of diabetes at all val-
ues of A1C. This suggests that, in our
dataset at least, 1,5AG levels will not be a
very useful clinical indicator of HNF1A-
MODY.Weinvestigatedthisquestionfur-
ther by constructing ROC curves. For
HNF1A-MODY and type 2 diabetes, the
areaunderthecurve(AUC)was0.60(Fig.
2B), conﬁrming that in our set of subjects
unadjusted 1,5AG levels are poorly dis-
criminative between HNF1A-MODY and
type 2 diabetes. We then repeated the
ROC curve analysis using 1,5AG levels
adjustedforA1C.ThisimprovedtheAUC
to 0.75.
Our most striking ﬁnding was that
subjects with GCK-MODY had a higher
1,5AG level than any of the other groups
(P0.0003forallpairwisecomparisons,
bothuncorrectedandcorrectedforA1C).
Figure 1 illustrates that the GCK-MODY
cases show good separation from other
kinds of diabetes. ROC curve analysis to
examine the discriminative accuracy of
1,5AG level for GCK-MODY (from type 2
diabetes)gaveanAUCof0.79inoursub-
jects (Fig. 2A). Similarly for GCK-MODY
versusHNF1Adiabeticsubjects,theAUC
was0.86(Fig.2C).Bothoftheseestimates
Pal and Associates
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values of 0.94 and 0.96, respectively.
We calculated threshold values of
1,5AG designed to reﬂect maximum sen-
sitivity and speciﬁcity in our dataset; for
GCK-MODY versus type 2 diabetes, a
1,5AG 11 g/ml gave a sensitivity and
speciﬁcity of 75% for identifying the
GCK-MODY cases, while 70% of the type
2diabetescasesfallbelowthiscutoff.For
GCK-MODY versus HNF1A-MODY,
1,5AG 7.5 g/ml gave sensitivity of
86%andspeciﬁcityof84%foridentifying
GCK-MODY, while 89% of HNF1A-
MODYdiabeticsubjectshad1,5AGlevels
below this.
In clinical practice, A1C 8% and
FPG 5.5–8.5 mmol/l are often used as
biochemical discriminators to identify
those individuals with apparent mono-
genic diabetes most likely to have GCK-
MODY (12). In our dataset, these criteria
did not perform as well as 1,5AG. Al-
though they gave similar sensitivity to the
above for identifying GCK-MODY cases,
speciﬁcities were much lower at 42, 58,
and66%forA1C,FPG,andthecombined
criteria, respectively.
We examined how serum 1,5AG
could perform as a preselection for cases
for GCK diagnostic sequencing. This was
donebyestimatingtheproportionofpos-
itive tests for GCK-MODY that would be
identiﬁed by setting different prevalences
of GCK-MODY in the baseline sample set
using the threshold levels described
above. When the type 2 diabetes and
GCK-MODY groups from this study are
combined, 25% of cases in this combined
group with a 1,5AG value 11 g/ml
have a GCK mutation. This would be a
similar rate of positive test pick-up to that
achieved using standard clinical criteria
bytheU.K.diagnostictestingcenter(17).
However, the prevalence of GCK-MODY
in this combined group is 10%, which is
somewhat higher than we would expect,
even in a group referred for genetic inves-
tigation. Recalculating based on a more
realisticprevalenceofGCK-MODYrepre-
senting 5% of the diabetes cases would
halve the positive test rate to 12.5%,
which would probably still be an accept-
able pick-up rate given the changes in
management and prognosis that result
from rediagnosing type 1 or type 2 diabe-
tes as a GCK mutation. This is also com-
parable with many other diagnostic
genetic tests in the U.K. Other models
that add fasting glucose and A1C thresh-
olds to the calculation do not improve
these rates in our dataset.
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254 DIABETES CARE, VOLUME 33, NUMBER 2, FEBRUARY 2010 care.diabetesjournals.orgCONCLUSIONS — Identifying mo-
nogenic forms of diabetes and assigning
the subtypes correctly currently depends
on recognizing a clinical phenotype and
arrangingconﬁrmatorymoleculartesting.
Additional biochemical tests that aid pri-
oritization of cases for genetic testing
would have great clinical utility.
1,5AG is an attractive candidate
marker for HNF1A-MODY because it uti-
lizestheknowncharacteristicoflowrenal
threshold for glucose seen in HNF1A mu-
tations. We conﬁrm the previous ﬁnding
(4)that1,5AGlevelsarelowerinHNF1A-
MODY than type 2 diabetes, but this dif-
ference is only apparent after adjustment
for A1C. This is necessary because the
lower A1C in our HNF1A-MODY group
(7.2 vs. 7.8%, P  0.04) has the effect of
diminishing the difference in unadjusted
1,5AG levels (the previous study was well
matched at baseline for A1C). Adjusting
for A1C increased the discriminative ac-
curacy of 1,5AG to identify HNF1A-
MODYfromtype2diabeteswiththeAUC
oftheROCcurverisingfrom0.60to0.75.
Thisisstillofratherlimitedclinicalutility
(AUC of 0.8 representing a useful test)
and would require further validation to
design a suitable model that includes
A1C. Ideally this validation would in-
clude more HNF1A-MODY cases with
higher A1C, as we have limited data on
A1C 9%. A further limitation for a role
of 1,5AG in a diagnostic strategy to detect
HNF1A-MODY is that we found no dif-
ference in 1,5AG levels between HNF1A-
MODY and either form of autoimmune
diabetes.
Themoststrikingﬁndinginourstudy
was the higher 1,5AG levels in subjects
with GCK-MODY compared with all
other groups. This is likely to be ex-
plained by the known modest postchal-
lenge glucose increment seen in those
with GCK mutations (18). Postprandial
glucose levels rarely rise high enough to
cause glycosuria, resulting in levels of
Figure 1—Scatter plots of serum 1,5AG levels (g/ml) versus A1C (%) for the different subtypes of diabetes. For clarity the data points are plotted
onthreepanelswithaﬁlledsymboltoemphasizeadifferentdiabeticsubtypeineachpanel:lilacdiamonds,subjectswithautoimmunediabetes(type
1	LADAcombined);bluecircles,type2diabetes;orangesquares,HNF1A-MODY;andgreensquares,GCK-MODY.A:Distributionofautoimmune
diabetes. B: Type 2 diabetes. C: Both MODY subtypes. Three subjects with A1C 12.5% are not shown for increased clarity of the ﬁgure but were
included in the analysis.
Figure2—ROCcurvesillustratingdiscriminativecapacityofunadjusted1,5AGtodistinguishbetweendiabetessubgroups.A:GCK-MODYandtype
2 diabetes. B: HNF1A-MODY and type 2 diabetes. C: GCK-MODY and HNF1A-MODY.
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range. Our ROC curve analyses result in
promising estimates for the ability of
1,5AG to discriminate GCK-MODY from
both type 2 diabetes and HNF1A-MODY.
Though 1,5AG levels are likely to be
inﬂuenced by recent dietary intake, we
made no attempt to adjust for this. The
ROC curve results are reassuring that this
test will perform well in routine clinical
practice where prior dietary information
is not likely to be available.
There are some limitations to extrap-
olating this ﬁnding to a general type 2
diabetes clinic population: The subjects
in this study were selected for age of di-
agnosis 45 years, where the pretest
probability of possessing a GCK mutation
islikelytobehigherthaninanunselected
group of patients with type 2 diabetes
(GCK mutations in fasting hyperglycemia
fall from a prevalence of 40% in children
[19] to 
1% in adults diagnosed over 50
years of age [20]). In the 45 years of age
range the likely prevalence of GCK muta-
tions is difﬁcult to estimate but probably
in the range of 3–5%.
We found that duration of diabetes did
not have a signiﬁcant effect on 1,5AG level;
however,thetype2diabeticpatientsondiet
treatmenthadahigher1,5AGthanthoseon
oral hyperglycemic agents or insulin. This
suggests that postprandial glucose excur-
sion is not normalized by treatment of dia-
betes. Therefore, we would predict that
1,5AG levels might be less useful in dis-
criminating GCK-MODY from those
with type 2 diabetes who are well-
controlled on diet treatment.
There was very little overlap between
the 1,5AG levels in our GCK-MODY and
HNF1A-MODY groups. This discrimina-
tive performance beneﬁts from the fact
that two major characteristics of these
subtypes of MODY (low renal threshold
and low postchallenge increment) have
opposite effects on 1,5AG levels and sug-
gests 1,5AG analysis might have the most
potential as a discriminative test between
these two MODY subtypes. Currently pa-
tients suspected of having MODY are fre-
quently selected for GCK rather than
HNF1A mutation testing on the basis of
thecharacteristicpatternseenonOGTTs:
InGCK-MODYamildfastinghyperglyce-
mia with a modest 2-h increment (90th
centile 4.6 mmol/l) is observed (12),
whileinHNF1A-MODYFPGmaybenor-
mal but with a high 2-h postchallenge
level (mean 5 mmol/l) (18).
Although an OGTT is quoted as the
goldstandardinvestigation(12),itistime
consuming, difﬁcult to interpret in those
on treatment, and has large day-to-day
variability (21). A 1,5AG measurement
would in theory be a useful, more cost-
effective, and practical alternative to an
OGTT, as it reﬂects postprandial glucose
excursion from a single nonfasting blood
sample. OGTT data were not available on
our GCK-MODY cases, so we were not
able to directly assess the correlation with
2-h glucose. However, a relationship be-
tween 1,5AG levels and OGTT has been
examined previously; in subjects with
IGT1,5AGlevelswerestronglycorrelated
(r  0.8) with 2-h glucose levels, and
this was greater than the correlation seen
with FPG and the correlation between
A1C and either fasting or 2-h values (22).
Similarly, 1,5AG levels showed good cor-
relation with postprandial continuous
glucose monitoring system readings (23)
and 2-h postprandial capillary measure-
ments (24). This supports the use of
1,5AG as a surrogate for postchallenge
glucose and merits further validation in
GCK-MODY.
In conclusion, we suggest future re-
search should focus on the role of the
1,5AG level as a tool to differentiate
MODY subtypes in those already sus-
pected of having a monogenic form of
diabetes.
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